Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618319 · ClinicalTrials.gov registry record · Phase 2
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)
A Phase 2 study of GIST, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT00618319 is a Phase 2 study of GIST that has completed, run by Biogen. The registered enrollment target is 20 participants, below the 134-participant average among 8 other GIST trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00618319, a Phase 2 study of GIST, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will examine the effect of BIIB021 on GIST growth and metabolism.
Conditions Studied
Interventions
- DRUG BIIB021
Study Locations (3)
California
- Reseach Facility - Encinitas
- Research Site - Santa Monica
Texas
- Reseach Facility - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618319
The ClinicalTrials.gov registry entry for NCT00618319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 134-participant average among 8 other GIST trials with a reported enrollment target (85% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GIST appearing as the primary indexed condition, and to 1 intervention - of which BIIB021 is the first listed.
NCT00618319 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT00618319 about?
NCT00618319 is a clinical study titled "An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)". This study will examine the effect of BIIB021 on GIST growth and metabolism.
What is the current status of trial NCT00618319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2008-02. Estimated completion is 2010-04.
What conditions does trial NCT00618319 study?
This clinical trial studies the following conditions: GIST.
What interventions are being tested in trial NCT00618319?
The interventions under investigation include: BIIB021 (DRUG).
Who is sponsoring clinical trial NCT00618319?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00618319 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GIST
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RECRUITING · Phase 1
-
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
RECRUITING · Phase 1
-
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.